Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Neuropsychopharmacology ; 29(4): 759-69, 2004 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-14970832

RESUMO

Elevated basal intracellular calcium (Ca(2+)) levels ([Ca(2+)](B)) in B lymphoblast cell lines (BLCLs) from bipolar I disorder (BD-I) patients implicate altered Ca(2+) homeostasis in this illness. Chronic lithium treatment affects key proteins modulating intracellular Ca(2+) signaling. Thus, we sought to determine if chronic exposure to therapeutic lithium concentrations also modifies intracellular Ca(2+) homeostasis in this surrogate cellular model of signal transduction disturbances in BD. BLCLs from BD-I (N=26) and healthy subjects (N=17) were regrown from frozen stock and incubated with 0.75 mM lithium or vehicle for 24 h (acute) or 7 days (chronic). [Ca(2+)](B), lysophosphatidic acid (LPA)-stimulated Ca(2+) mobilization ([Ca(2+)](S)), and thapsigargin-induced store-operated Ca(2+) entry (SOCE) were determined using ratiometric fluorometry with Fura-2. Compared with vehicle, chronic lithium exposure resulted in significantly higher [Ca(2+)](B) (F=8.47; p=0.006) in BLCLs from BD-I and healthy subjects. However, peak LPA-stimulated [Ca(2+)](S) and SOCE were significantly reduced (F=11.1, p=0.002 and F=8.36, p=0.007, respectively). Acute lithium exposure did not significantly affect measured parameters. In summary, the effect of chronic lithium to elevate [Ca(2+)](B) in BLCLs while attenuating both receptor-stimulated and SOCE components of intracellular Ca(2+) mobilization in BLCLs suggests that modulation of intracellular Ca(2+) homeostasis may be important to the therapeutic action of lithium.


Assuntos
Cálcio/metabolismo , Homeostase/efeitos dos fármacos , Espaço Intracelular/efeitos dos fármacos , Lítio/farmacologia , Adulto , Linfócitos B/efeitos dos fármacos , Linfócitos B/virologia , Transtorno Bipolar/tratamento farmacológico , Estudos de Casos e Controles , Contagem de Células , Linhagem Celular , Transformação Celular Viral/efeitos dos fármacos , Distribuição de Qui-Quadrado , Esquema de Medicação , Inibidores Enzimáticos/farmacologia , Feminino , Fura-2/metabolismo , Herpesvirus Humano 4/metabolismo , Humanos , Espaço Intracelular/metabolismo , Lítio/uso terapêutico , Lisofosfolipídeos/farmacologia , Masculino , Análise Multivariada , Tapsigargina/farmacologia , Fatores de Tempo
2.
World J Biol Psychiatry ; 11(6): 803-12, 2010 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-20586531

RESUMO

UNLABELLED: Tardive dyskinesia (TD) is a severe and potentially irreversible motor side effect linked to long-term antipsychotic exposure. Changes in dopamine neurotransmission have been implicated in the etiology of TD, and catechol-O-methyl-transferase (COMT) is an enzyme that metabolizes dopamine. OBJECTIVES: We investigated five single-nucleotide polymorphisms in addition to the functional Val158Met variant spanning the COMT gene for association with TD. METHODS: We analyzed the six COMT single-nucleotide polymorphisms in a sample of schizophrenia/schizoaffective disorder patients (n=226; 196 Caucasians and 30 African Americans). RESULTS: We found a significant association between the marker rs165599 in the 3' untranslated region of COMT and TD (AA versus G-carrier: OR(AA)=2.22, 95% CI:1.23-4.03; P=0.007). The association appeared to be originating from males. We did not find a significant association of the other five tested polymorphisms with TD in our samples. We performed a sex-stratified meta-analysis across all of the published studies (n=6 plus our own data) of COMT and TD, and found an association between ValVal genotype and TD in females (OR(ValVal)=1.63, 95% CI: 1.09-2.45; P=0.019) but not in males. CONCLUSIONS: Overall, our results suggest that the COMT gene may have a minor but consistent role in TD, although sex-stratified studies with additional markers in larger clinical samples should be performed.


Assuntos
Catecol O-Metiltransferase/genética , Transtornos dos Movimentos/genética , Polimorfismo de Nucleotídeo Único/genética , Esquizofrenia/genética , Adulto , Análise de Variância , Antipsicóticos/efeitos adversos , Antipsicóticos/uso terapêutico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Transtornos dos Movimentos/etiologia , Razão de Chances , Esquizofrenia/tratamento farmacológico , Distribuição por Sexo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA